RCS - Coiled Therapeutics - Presentation at 18th Annual World Cancer Congress

Coiled TherapeuticsAnnouncement

15/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260415:nRSO2589Aa&default-theme=true

RNS Number : 2589A  Coiled Therapeutics PLC  15 April 2026

15 April 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

 

Presentation at the 18(th) Annual World Cancer Congress

 

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company
developing precision medicines for hard-to-treat cancers, today announces that
its Executive Chairman, Dr. Sotirios G. Stergiopoulos, will be a featured
speaker at the 18(th) Annual World Cancer Congress, taking place in Athens
this week on 15 - 17 April 2026
(https://www.bitcongress.com/cancer2026/default.asp
(https://www.bitcongress.com/cancer2026/default.asp) ).

 

Dr. Stergiopoulos will deliver a presentation on 16 April 2026, titled: "Novel
TACC3 Protein-Protein Interaction Inhibitor, AO-252, A Key Driver in Cancer
Functions Such as DDR, Immune Evasion and CIN, Shows Potent Activity in
Multiple Solid Tumors Along with Brain Metastasis."

 

The presentation will highlight the latest findings on the Company's lead
candidate, AO-252, a first-in-class TACC3 inhibitor, and its potential to
address significant unmet needs in oncology, including the treatment of brain
metastases.

 

This presentation follows the Company's recent clinical trial update which
demonstrated a superior efficacy profile and durable clinical responses for
AO-252 in a heavily pre-treated patient population.

 

 

 

Enquiries:

 Coiled Therapeutics plc

 Sotirios Stergiopoulos (Chairman)                                          Via Burson Buchanan

 Sridhar Vempati (CEO)

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)  +44 (0)20 3470 0470

 David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Shard Capital Partners LLP (Joint Broker)                            +44 (0)20 4530 6926

 Damon Heath

 CPS Capital Group Pty Ltd (Joint Broker)                             +61 (0)8 9223 2222

 Jason Peterson / David Valentino

 Burson Buchanan (Public Relations)                                   +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 

 

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology
company focused on developing innovative precision oncology therapies. Its
lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I
clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is
actively enrolling patients to test for safety and efficacy in patients whose
cancer has progressed on other treatments.   The Company is also assessing
its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is
supported by a leadership team with a proven track record in drug development
and strategic backing from A2A Pharmaceuticals.

 

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small
molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3
(TACC3). TACC3 is a validated oncology target that is frequently overexpressed
in many aggressive, hard-to-treat solid tumours but is dispensable in normal
adult cells, providing a wide therapeutic window.

 

By selectively disrupting cancer-critical protein-protein interactions at the
TACC3 C-terminal domain, AO-252 induces mitotic and replication stress,
impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has
demonstrated the ability to cross the blood-brain barrier, addressing a
significant unmet medical need for the treatment of brain metastases.

 

The asset is currently in an ongoing Phase I open-label dose-escalation study
and early clinical signals have shown encouraging anti-tumour activity and a
benign safety profile, with the Company planning to initiate dose expansion
cohorts in lead indications, including prostate and ovarian cancer, during
2026.

 

For more information, please visit: www.coiledplc.com
(http://www.coiledplc.com/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUGACUPQGCW



            Copyright 2019 Regulatory News Service, all rights reserved